Share This Page

Support & Insight for the Autumn of Life

New Alzheimer’s Drug Lecanemab: High price tag, Moderate warnings

Mayo Clinic on lecanemab
The FDA has approved generic lecanemab (brand name Leqembi®). The new drug can slow the progression of Alzheimer’s. Two top doctors discuss the pros and cons. (Video)

The Food and Drug Administration (FDA) has granted traditional approval for generic lecanemab (brand name Leqembi®). The new treatment promises to slow the decline of memory and thinking in some Alzheimer’s patients.

Dr. Kavita Patel joined Alicia Menendez on American Voices to discuss the drug’s benefits, risks and what it means for caregivers. 

Lecanemab is a monoclonal antibody that has shown promise in removing amyloid plaques from the brain, according to phase 3 trial results.

See Dr. Ronald Petersen, a neurologist and director of the Mayo Clinic Alzheimer’s Disease Research Center, describe Lecanemab’s therapeutic ability to slow Alzheimer’s by removing amyloid plaques. These plaques are one of the defining features of Alzheimer’s disease.


SOURCES:

  • MSNBC YouTube Channel
  • Mayo Clinic YouTube Channel
  • Email me when people comment
    Notify of
    guest

    0 Comments
    Inline Feedbacks
    View all comments
    Hanna Levi Julian

    Hanna Levi Julian

    This site was inspired by my Mom’s autoimmune dementia.

    It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

    The site is dedicated to all those preserving the dignity of the community of people living with dementia.

    Peter Berger, Editor

    Share this page To

    Related:

    Share to Facebook
    Twitter
    LinkedIn

    This site was inspired by my Mom’s autoimmune dementia.

    It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

    The site is dedicated to all those preserving the dignity of the community of people living with dementia.

    Peter Berger, Editor

    Visit Alzheimer's Weekly On

    0
    Would love your thoughts, please comment.x
    ()
    x
    News, Treatments, Care Tips

    Subscribe To The Alzheimer's & Dementia Weekly Newsletter

    videos & articles on Research & Prevention
    News to Get at the Truth

    Subscribe To Our Weekly Newsletter

    ×